A Trial of ZL-1201 in Subjects With Advanced Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 65
Summary
- Conditions
- Advanced Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a first-in-human, dose escalation trial of an anti-CD47 antibody. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials. This study is composed of 3 stages: Part 1 dose escalation withou...
This is a first-in-human, dose escalation trial of an anti-CD47 antibody. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials. This study is composed of 3 stages: Part 1 dose escalation without priming dose, and Part 2 dose escalation with priming dose. Part 3 pharmacodynamic (PD)/ dose expansion cohort will open after the completion of Part 1 and 2.
Tracking Information
- NCT #
- NCT04257617
- Collaborators
- PPD
- Investigators
- Principal Investigator: Alex A Adjei, PhD Mayo Clinic College of Medicine and Science
Get Well Soon